These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 11029513

  • 1. Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines.
    Westphalen S, Kotulla G, Kaiser F, Krauss W, Werning G, Elsasser HP, Nagy A, Schulz KD, Grundker C, Schally AV, Emons G.
    Int J Oncol; 2000 Nov; 17(5):1063-9. PubMed ID: 11029513
    [Abstract] [Full Text] [Related]

  • 2. Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system.
    Günthert AR, Gründker C, Bongertz T, Schlott T, Nagy A, Schally AV, Emons G.
    Am J Obstet Gynecol; 2004 Oct; 191(4):1164-72. PubMed ID: 15507937
    [Abstract] [Full Text] [Related]

  • 3. Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphatase.
    Gründker C, Völker P, Emons G.
    Endocrinology; 2001 Jun; 142(6):2369-80. PubMed ID: 11356684
    [Abstract] [Full Text] [Related]

  • 4. Luteinizing hormone-releasing hormone (LHRH) inhibits apoptosis induced by cytotoxic agent and UV-light but not apoptosis mediated through CD95 in human ovarian and endometrial cancer cells.
    Günthert AR, Gründker C, Böttcher B, Emons G.
    Anticancer Res; 2004 Jun; 24(3a):1727-32. PubMed ID: 15274347
    [Abstract] [Full Text] [Related]

  • 5. High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines.
    Emons G, Schröder B, Ortmann O, Westphalen S, Schulz KD, Schally AV.
    J Clin Endocrinol Metab; 1993 Dec; 77(6):1458-64. PubMed ID: 8263128
    [Abstract] [Full Text] [Related]

  • 6. Experimental therapy of doxorubicin resistant human uveal melanoma with targeted cytotoxic luteinizing hormone-releasing hormone analog (AN-152).
    Oláh G, Dobos N, Vámosi G, Szabó Z, Sipos É, Fodor K, Harda K, Schally AV, Halmos G.
    Eur J Pharm Sci; 2018 Oct 15; 123():371-376. PubMed ID: 30076951
    [Abstract] [Full Text] [Related]

  • 7. Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice.
    Gründker C, Völker P, Griesinger F, Ramaswamy A, Nagy A, Schally AV, Emons G.
    Am J Obstet Gynecol; 2002 Sep 15; 187(3):528-37. PubMed ID: 12237622
    [Abstract] [Full Text] [Related]

  • 8. High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines.
    Emons G, Ortmann O, Becker M, Irmer G, Springer B, Laun R, Hölzel F, Schulz KD, Schally AV.
    Cancer Res; 1993 Nov 15; 53(22):5439-46. PubMed ID: 8221683
    [Abstract] [Full Text] [Related]

  • 9. Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152.
    Emons G, Sindermann H, Engel J, Schally AV, Gründker C.
    Neuroendocrinology; 2009 Nov 15; 90(1):15-8. PubMed ID: 19521066
    [Abstract] [Full Text] [Related]

  • 10. Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers.
    Gründker C, Völker P, Schulz KD, Emons G.
    Gynecol Oncol; 2000 Aug 15; 78(2):194-202. PubMed ID: 10926802
    [Abstract] [Full Text] [Related]

  • 11. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
    Engel J, Emons G, Pinski J, Schally AV.
    Expert Opin Investig Drugs; 2012 Jun 15; 21(6):891-9. PubMed ID: 22577891
    [Abstract] [Full Text] [Related]

  • 12. Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers.
    Nagy A, Schally AV.
    Biol Reprod; 2005 Nov 15; 73(5):851-9. PubMed ID: 16033997
    [Abstract] [Full Text] [Related]

  • 13. Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207.
    Engel JB, Keller G, Schally AV, Nagy A, Chism DD, Halmos G.
    Fertil Steril; 2005 Apr 15; 83 Suppl 1():1125-33. PubMed ID: 15831285
    [Abstract] [Full Text] [Related]

  • 14. In vitro targeting of a cytotoxic analog of luteinizing hormone-releasing hormone AN-207 to ES-2 human ovarian cancer cells as demonstrated by microsatellite analyses.
    Arencibia JM, Schally AV, Halmos G, Nagy A, Kiaris H.
    Anticancer Drugs; 2001 Jan 15; 12(1):71-8. PubMed ID: 11272290
    [Abstract] [Full Text] [Related]

  • 15. LHRH might act as a negative autocrine regulator of proliferation of human ovarian cancer.
    Emons G, Weiss S, Ortmann O, Gründker C, Schulz KD.
    Eur J Endocrinol; 2000 Jun 15; 142(6):665-70. PubMed ID: 10832105
    [Abstract] [Full Text] [Related]

  • 16. Effect of gonadotropin-releasing hormone analogs and their conjugates on gonadotropin-releasing hormone receptor--positive human cancer cell lines.
    Pályi I, Vincze B, Kálnay A, Turi G, Mezõ I, Teplán I, Seprõdi J, Pató J, Móra M.
    Cancer Detect Prev; 1996 Jun 15; 20(2):146-52. PubMed ID: 8706040
    [Abstract] [Full Text] [Related]

  • 17. Antitumor effects of cecropin B-LHRH' on drug-resistant ovarian and endometrial cancer cells.
    Li X, Shen B, Chen Q, Zhang X, Ye Y, Wang F, Zhang X.
    BMC Cancer; 2016 Mar 28; 16():251. PubMed ID: 27021903
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone.
    Yano T, Pinski J, Radulovic S, Schally AV.
    Proc Natl Acad Sci U S A; 1994 Mar 01; 91(5):1701-5. PubMed ID: 8127868
    [Abstract] [Full Text] [Related]

  • 19. Luteinizing hormone-releasing hormone induces nuclear factor kappaB-activation and inhibits apoptosis in ovarian cancer cells.
    Gründker C, Schulz K, Günthert AR, Emons G.
    J Clin Endocrinol Metab; 2000 Oct 01; 85(10):3815-20. PubMed ID: 11061544
    [Abstract] [Full Text] [Related]

  • 20. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.
    Seitz S, Buchholz S, Schally AV, Weber F, Klinkhammer-Schalke M, Inwald EC, Perez R, Rick FG, Szalontay L, Hohla F, Segerer S, Kwok CW, Ortmann O, Engel JB.
    BMC Cancer; 2014 Nov 19; 14():847. PubMed ID: 25410881
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.